6:07 AM ET
8-K
Licensing Deal
Zymeworks Licensing Deal with Roche Worth $813M
Zymeworks entered into a global collaboration and license agreement with Roche for the development and commercialization of ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive a $55 million upfront payment and a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional milestones plus tiered royalties.
- Value
- $813M
- Counterparty
- Roche